Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Similar documents
Aortic valve implantation using the femoral and apical access: a single center experience.

Pacemaker After Transcatheter Aortic Valve Implantation: Where, When and How?

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Reverse left atrium and left ventricle remodeling after aortic valve interventions

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Echo Assessment Pre-TAVI

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

Supplementary Online Content

Congestive Heart Failure or Heart Failure

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Hafþór Ingi Ragnarsson. Thesis for the Degree of Bachelor of Science University of Iceland Faculty of Medicine School of Health Sciences

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

TAVI in Korea, How to Avoid Conduction

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Pacemaker rates Second generation TAVI Devices

Transcatheter aortic valve implantation and pre-procedural risk assesment

TAVR: Echo Measurements Pre, Post And Intra Procedure

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Management of Difficult Aortic Root, Old and New solutions

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

Bi-Ventricular pacing after the most recent studies

TAVR : Caring for your patients before and after TAVR

Optimal Imaging Technique Prior to TAVI -Echocardiography-

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

TAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology

PRESENTER DISCLOSURE INFORMATION. There are no potential conflicts of interest regarding current presentation

Indication, Timing, Assessment and Update on TAVI

The Ross Procedure: Outcomes at 20 Years

CoreValve in a Degenerative Surgical Valve

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Worldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates

Interventional solutions for atrial fibrillation in patients with heart failure

AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Clinical Case 1 A patient with a syncope Panos E. Vardas President Elect of the ESC, Prof of Cardiology, University Hospital of Crete

Clinical and hemodynamic effects of transcatheter aortic valve implantation Yong, Z.Y.

TAVR SPRING 2017 The evolution of TAVR

Emergency Intraoperative Echocardiography

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Complications after TAVI: VARC Definitions, Frequency and Management Considerations Patrick W. Serruys, Nicolo Piazza,

Natural History and Echo Evaluation of Aortic Stenosis

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

Echocardiographic changes after aortic valve replacement: Does the failure rate of mitral valve change? Original Article

Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease

Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France

Dr Winnie Sze-Wun Chan. Cardiac Team Deputy Team Head Department of Radiology and Imaging Queen Elizabeth Hospital Hong Kong

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.

PM indications before and after TAVI

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic

Welcome 17 Michigan TAVR Participating Hospitals!

Spotlight on Valvular Heart Disease Guidelines

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Nouvelles indications/ Nouvelles valves

Portico (St. Jude Medical Inc, St.

Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Strokes After TAVR Reasons for Declining Frequency

Valvular Guidelines: The Past, the Present, the Future

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

History. 2D echo before TAVI. 88 female Hypertensive - hyperlipidemic History of LOC syncope Echo: severe AS AV gradient 90 mmhg Good LV LVH

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium

LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR?

Supplementary Online Content

Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification

Management of HOCM: Non-Surgical Options

42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim

NON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

Transcription:

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Ömer Aktug 1, MD; Guido Dohmen 2, MD; Kathrin Brehmer 1, MD; Verena Deserno 1 ; Ralf Herpertz 1 ; Rüdiger Autschbach 2, MD; Robert Stöhr 1, MD; Nikolaus Marx 1, MD; Rainer Hoffmann 1, MD 1 Department of Cardiology, Pneumology and Angiology, University Hospital of RWTH Aachen, Germany 2 Department of Cardiac and Thoracic Surgery, University Hospital of RWTH Aachen, Germany

Conflict Of Interest - Disclosure Within the past 12 months, I have had a financial interest/ arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company 1. Honoraria for lectures no 2. Honoraria for advisory board activities no 3. Participation in clinical trials no 4. Research funding no

Background Aortic stenosis (AS) is a consistently progressive disease that affects 2-7% of individuals older than age 65 with associated impact on morbidity and mortality Aortic valve replacement (AVR) is the most common heart valve procedure Since the initiation of transcatheter aortic valve implantation (TAVI) in 2002, there has been increasing interest in the field of catheter-based treatment of high surgical-risk and non-operable patients with symptomatic AS There is a high incidence of early alterations in atrioventricular/ interventricular conduction after TAVI and need for pacemaking

Dawkins S. Ann Thorac Surg 2008; 85:108-12 Thomas JL. J Thorc Cardiovasc Surg 1982; 84:382-386 El-Khally Z. Am J Cardiol 2004; 94:1008-11 Conduction Defects In Surgical AVR Left Bundle Branch Block (LBBB) Thomas JL (1982) 31.6 % Ziad El-Khally (2004) 5.7 % AV-Block (AVB) Gannon PG (1965) 12.5 % Kalusche D (1986) 0.9 % Morell VO (2006) 6.5 % Global defects Koplan (2003) 5.1 % Associated with increased incidence of cardiac events*!! specifically syncope, AV dissociation and sudden death

Conduction Defects In TAVI Conduction disturbances (LBBB, AV-Block) and need for pacemaker implantation have also been reported after TAVI LBBB is associated with left ventricular mechanical dyssynchrony, left ventricular remodeling and impaired systolic and diastolic heart function However, there were few small systematic analyses on the frequency of conduction disturbance and in particular LBBB after TAVI

Aim Of Study Evaluation of frequency and possible predictors of Left Bundle Branch Block (LBBB) after TAVI using CoreValve TM as well as Edwards SAPIEN TM valve prosthesis

RWTH University Of Aachen Experience January 2008 December 2010 205 pts mean age 73 (m), 132 (f) 80 ± 7 years

Patients Selection I Inclusion criteria: Severe aortic valve stenosis, AVA <1 cm 2, with severe symptoms related to AS Aortic valve annulus diameter 18 mm and 27 mm Femoral or iliacal artery >7mm and absence of stenosis Patients referred for TAVI after a senior cardiologist and senior cardiac surgeon reached consensus that surgical replacement would be associated with either high or prohibitive risk or contraindications for surgery

Patients Selection II Contraindications: Bicuspid aortic valve Asymmetric heavy valvular calcification Aortic root dimension >45 mm Presence of LV apical thrombus Not in patients with life expectancy < 1 year (conservative treatment)

Arrhythmic Evaluation Pre-procedure Basal ECG 12-Lead Post-procedure 24-48h If after 48 h there is spontaneous rhythm, remotion of temporary pacing and carry out Holter ECG monitoring If after 48 h patient is still paced, implantation of permanent pacemaker (PPM) Folluw-up post-procedure ECG 12-leads pre-discharge Potential clinical, ECG, angiographic and echocardiographic predictors of permanent pacing requirement were studied

Patient Characteristics (n=205) N (%) Age (yrs), mean ±SD 80 ± 7 Male 73 (36) Coronary artery disease 132 (64) NYHA classification ( II) 175 (85) LV-EF (EF 45%) 143 (70) Diabetes 55 (27) Hypertension 193 (94) Hypercholesterolemia 127 (62) Renal insufficiency 85 (41) Smoker 46 (22) LA size (mm) 40.5 ± 6.7 LVEDD (mm) 47.2 ± 7.3 LVH 152 (74) Aortic valve area, preprocedural (cm 2 ) 0.7± 0.2 Agatston score 2225 ± 1341 LVOT diameter (mm), mean ±SD 19.5 ± 2.3 Aortic annulus diameter (mm), mean ±SD 22.4 ± 2.5 Prosthesis type CoreValve Edwards-SAPIEN Prosthesis inflow size CoreValve 26-mm 29-mm 96 (47) 109 (53) 52 (58) 38 (42) Edwards SAPIEN 23-mm 26-mm 27 (26) 76 (74) LVOT =left ventricular outflow tract; LV-EF= left ventricular ejection function; LA= left atrium; LVEDD= left ventricular enddiastolic diameter; LVH= left ventricular hypertrophy Aktug et al. Int J Cardiol, in press

Pre-implant Analysis n (%) Sinusrhythm 107 (52) Atrial fibrillation 53 (26) PPM 10 (3) AV-Block >1

Immediate POST-IMPLANT 23% 27% 3% SR 47% AF Complete AVB Complete AVB+AV delay

30-days Follow-up Methods: 12-lead ECG Pre Implantation (n=205) Post Implantation (n=185) LBBB 20 (9.7%) 52 (28.1%) CoreValve 9 (10.4%) 37 (38.5%) 30-day FU (n=179) * 28 (15.6%) 22 (12.3%) Edwards- Sapien 11 (10.1%) 15 (13.8%) 6 (3.3%) * 26 pts (=12.7%) died during FU

Characteristics Of Edwards vs CoreValve Patients Edwards n=109 CoreValve n=96 P Age, years 79 ± 7 82 ± 6 0.005 Gender, male 46 (42%) 28 (29%) 0.072 Ejection fraction - >60% - 55-60% - 45-54% - 35-44% - <35% 38 9 14 10 9 63 7 12 7 0 0.524 Annulus diameter, mm 22 ± 3 23 ± 3 0.343 LBBB pre (n) 11 (10%) 9 (9%) 0.345 LBBB post (n) 15 (14%) 37 (39%) 0.0004 Pacemaker implantation (n) 7 (6%) 37 (39%) <0.001 Prosthesis implantation depth, mm 6.6 ± 3.4 8.0 ± 3.0 <0.001 All-cause death, n 10 (9%) 16 (17%) 0.432

Characteristics Of Patients With And Without New LBBB After TAVI New LBBB n=52 No new LBBB (prior LBBB+no LBBB) n=153 Age, years 80 ± 5 80 ± 7 0.408 Gender, male 32 (44%) 41 (56%) 0.195 P Ejection fraction, % - >60-55-60-45-54-35-44 - <35 36 2 5 3 1 61 3 11 8 7 0.485 Annulus diameter, mm 22 ± 2 22 ± 2 0.916 Agatston Score 2116 ± 666 2045 ± 719 0.438 Valve type - CoreValve - Edwards 37 (38.5%) 15 (13.8%) 59 (61.5%) 94 (86.2%) 0.0004 Left ventricular hypertrophy 41 (79%) 87 (57%) 0.480 Pacemaker implantation 16 (31%) 25 (16%) 0.061 Prosthesis diameter to aortic annulus diameter ratio 1.2 ± 0.2 1.2 ± 0.2 0.170 Prosthesis implantation depth, mm 9.4 ± 2.5 6.4 ± 3.2 <0.001 All-cause death, n 5 (10%) 22 (14%) 0.228

Predictors Of New LBBB After TAVI Univariate Analysis OR 95% CI P Prosthesis type being CoreValve 2.639 1.314-5.813 0.007 Valve implantation depth into the left ventricular outflow tract (per mm) 1.185 1.064-1.320 0.002 Ratio of prothesis diameter to aortic annulus diameter 1.186 0.958-1.465 0.117 Multivariate Analysis OR 95% CI P Prosthesis type being CoreValve 0.593 0.256-1.374 0.223 Valve implantation depth into the left ventricular outflow tract (per mm) 1.172 1.035-1.327 0.012

Conclusions TAVI is frequently associated with new LBBB. New LBBB is transient in approx. 50% of pts and may disappear after 30 days. Frequency of new LBBB is higher after implantation of the CoreValve than after implantation of the Edwards prosthesis. The only predictor of new LBBB is implantation depth of the prosthesis. An implantation depth >8 mm is related to a higher incidence of LBBB.

Thanks For Your Attention!